The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2022 | How MRD assessment can inform treatment decisions in AML
Thomas Cluzeau, MD, PhD, Central University Hospital of Nice, Nice, France, shares some insights into how measurable residual disease (MRD) assessment can inform treatment decisions in acute myeloid leukemia (AML), highlighting the importance of MRD as a predictive marker for long-term survival and as a method of evaluating the efficiency of therapeutic agents. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
